|
POU5F1P3
|
Malignant neoplasm of breast
|
0.100 |
Biomarker |
BEFREE |
EpCAM overexpression increases the expression of stemness markers (NANOG，SOX2, and OCT4) and EMT markers (N-cadherin and vimentin) under the condition of hypoxia in BC.
|
31584203 |
2020 |
|
POU5F1P3
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression |
BEFREE |
Analysis by qPCR, ELISA, western blot, immunofluorescence staining, sphere formation, colony assay, transwell migration, and invasion assays demonstrated rBmK AGAP treatment decreased the expressions of Oct4, Sox2, N-cadherin, Snail, and increased the expression of E-cadherin. rBmK AGAP inhibited breast cancer cell stemness, EMT, migration, and invasion by down-regulating PTX3 through NF-κB and Wnt/β-catenin signaling Pathway <i>in vitro</i> and <i>in vivo</i>.
|
30740360 |
2019 |
|
POU5F1P3
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression |
BEFREE |
PD-L1 could promote the expression of stemness markers (OCT4 and Nanog) in breast cancer stem cells.
|
30803931 |
2019 |
|
POU5F1P3
|
Malignant neoplasm of breast
|
0.100 |
Biomarker |
BEFREE |
Correction to: Post-translational modification of OCT4 in breast cancer tumorigenesis.
|
31641242 |
2019 |
|
POU5F1P3
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression |
BEFREE |
Downregulation of FOXD2‑AS1 decreased the percentage of CD44 antigen+/signal transducer CD24- in breast cancer stem cell (BCSC) cells, and decreased the expression of numerous stem factors, including Nanog, octamer‑binding transcription factor 4 (Oct4), and sex determining region Y‑box 2 (SOX2), and inhibited the epithelial‑mesenchymal transition process.
|
30628646 |
2019 |
|
POU5F1P3
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression |
BEFREE |
OCT4 was down-regulated in breast cancer tissues, and the overexpression of OCT4 promoted MDA-MB-231 cell proliferation and inhibited the proliferation of MCF-7 cells in vitro and in vivo, respectively.
|
31012189 |
2019 |
|
POU5F1P3
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression |
BEFREE |
OCT4 is over-expressed in both of the breast cancer cell lines; MCF7 and MDA-MB-231 and its inhibition resulted in drastic decrease in rate of cell proliferation, metastatic ability and induced apoptosis.
|
29203199 |
2018 |
|
POU5F1P3
|
Malignant neoplasm of breast
|
0.100 |
Biomarker |
BEFREE |
To investigate the possible involvement of Oct4 in IR resistance of breast cancer cells, cells were transfected with Oct4.
|
29749438 |
2018 |
|
POU5F1P3
|
Malignant neoplasm of breast
|
0.100 |
Biomarker |
BEFREE |
This compound inhibits breast cancer cell proliferation and mammosphere formation in a dose-dependent manner and reduces the CD44<sup>high</sup>/CD24<sup>low</sup> subpopulation and aldehyde dehydrogenase (ALDH)-expressing cell population as well as the expression of the self-renewal-related genes <i>CD44</i>, <i>SOX2</i>, and <i>OCT4.</i><i>3</i>-<i>O</i>-<i>p</i>-Coumaroyltormentic acid preferentially reduced the protein levels of c-Myc, which is a CSC survival factor, by inducing c-Myc degradation.
|
30149665 |
2018 |
|
POU5F1P3
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression |
BEFREE |
Our data shows that PHGDH deficiency impairs the tumorsphere formation capacity in embryonal carcinoma stem-like cells (ECSLCs), breast cancer stem-like cells (BCSLCs) and patient-derived brain tumor-initiating cells (BTICs), which is accompanied by the reduced expression of characteristic stemness-promoting factors, such as Oct4, Nanog, Sox-2, and Bmi-1.
|
30250195 |
2018 |
|
POU5F1P3
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression |
BEFREE |
Regulation of CHIP expression and OCT4 protein stability is a considerable approach for breast cancer therapy.
|
29511337 |
2018 |
|
POU5F1P3
|
Malignant neoplasm of breast
|
0.100 |
Biomarker |
BEFREE |
This study adopted bioinformatics to predict the miRNA to regulate OCT4 gene and investigated its impact on breast cancer cell infiltration, migration, and proliferation.
|
29565493 |
2018 |
|
POU5F1P3
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression |
BEFREE |
In addition, previous studies indicated that OCT4 expression is augmented in cervical cancer and associated with poor prognosis, whereas OCT4 is down-regulated and correlated with good clinical outcomes in breast cancer.
|
30287838 |
2018 |
|
POU5F1P3
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression |
BEFREE |
Levels of BRCA1, BRCA2, and Bod1 in miR-142-3p-overexpressing cells as well as expression of miR-142-3p, Bod1, KLF4, and Oct4 in sorted CD44<sup>+</sup>/CD24<sup>-/low</sup> cells were determined by quantitative polymerase chain reaction. miR-142-3p overexpression resulted in a strong decline in breast cancer stem cell characteristics with a decrease in CD44, CD133, ALDH1, Bod1, BRCA2, and mammosphere formation as well as reduced survival after irradiation. miR-142-3p expression was strongly reduced in sorted CD44<sup>+</sup>/CD24<sup>-/low</sup> stem cells, while Bod1, Oct4, and KLF4 were overexpressed.
|
30091683 |
2018 |
|
POU5F1P3
|
Malignant neoplasm of breast
|
0.100 |
Biomarker |
BEFREE |
We address connections between TGF-β and the stem cell-related transcription factor (TF) Oct4 in BCa.
|
29526821 |
2018 |
|
POU5F1P3
|
Malignant neoplasm of breast
|
0.100 |
Biomarker |
BEFREE |
The findings of the current study indicated that Oct3, rather than Oct4, may serve as a novel clinical marker and a potential target for gene-specific therapy of breast cancer.
|
29620155 |
2018 |
|
POU5F1P3
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression |
BEFREE |
Particularly, Oct4 expression was associated with poor clinical outcome in patients with hormone receptor-positive breast cancer treated with tamoxifen.
|
28422735 |
2017 |
|
POU5F1P3
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression |
BEFREE |
Administration of paricalcitol leads to upregulation of JMJD3 that suppresses Oct4 expression and the stem cell-like characteristics in breast cancer.
|
28423536 |
2017 |
|
POU5F1P3
|
Malignant neoplasm of breast
|
0.100 |
GeneticVariation |
BEFREE |
All data demonstrated a distinctive expression pattern of OCT4 spliced variants in different types of breast cancer and provide further evidence for the involvement of embryonic genes in carcinogenesis.
|
27814277 |
2017 |
|
POU5F1P3
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression |
BEFREE |
Furthermore, it could be demonstrated that downregulation of Oct4 by microRNAs-299-3p in breast cancer and fibrosarcoma cells lead to a decreased invasiveness in a microfluidic chip assay.
|
28426762 |
2017 |
|
POU5F1P3
|
Malignant neoplasm of breast
|
0.100 |
Biomarker |
BEFREE |
This fact suggests that melatonin is effective against breast cancer stem cells inhibiting the cell viability via OCT 4.
|
27671309 |
2017 |
|
POU5F1P3
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression |
BEFREE |
PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation.
|
28614911 |
2017 |
|
POU5F1P3
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression |
BEFREE |
PTPRD knockdown also increased the CD44<sup>+</sup>/CD24<sup>-</sup> breast cancer stem cell (BCSC) population and the expression of the stem cell markers ALDH1 and OCT4.
|
29228728 |
2017 |
|
POU5F1P3
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression |
BEFREE |
POU5F1/Oct-4 expression levels in breast cancer tissues were significantly higher in both the SLN metastasis and non-SLN metastasis groups (P = 0.003 and P = 0.030, respectively).
|
26931354 |
2016 |
|
POU5F1P3
|
Malignant neoplasm of breast
|
0.100 |
Biomarker |
BEFREE |
In addition, increasing evidence has shown the involvement of another Oct factor, Oct-3/4, in mammary tumorigenesis, making Oct-3/4 an emerging prognostic marker of breast cancer and a molecular target for the gene-directed therapeutic intervention, prevention and treatment of breast cancer.
|
27044595 |
2016 |